期刊文献+

急性早幼粒细胞白血病的预后分析

下载PDF
导出
摘要 目的观察初治成人急性早幼粒细胞白血病(APL)患者的预后情况及影响因素。方法回顾性分析64例初诊成人APL患者的临床资料,总结预后差异及影响因素。结果完全缓解(CR)率为95.08%,3年总生存(OS)率为93.10%,3年无病生存(DFS)率为80%。单因素分析显示,t(15;17)伴附加染色体异常、初诊白细胞数≥20×10~9/L是影响APL患者OS和DFS的不良因素,而CD56阳性和初诊低白蛋白是影响APL患者DFS的不良因素。多因素分析显示,初诊白细胞计数≥20×10~9/L是影响APL患者OS的独立危险因素。CD56、初诊白细胞计数≥20×10~9/L、伴附加染色体异常是APL患者DFS的独立预后不良因素。结论 CD56阳性、初诊白细胞计数≥20×10~9/L、伴附加染色体异常是初治成人APL患者的独立预后不良因素。
机构地区 温州市中心医院
出处 《现代实用医学》 2018年第8期1021-1023,共3页 Modern Practical Medicine
基金 浙江省卫生厅平台项目(2016DTA010) 温州市科技局项目(Y20160117)
  • 相关文献

参考文献3

二级参考文献28

  • 1孙爱宁,周海侠,吴德沛,王玮,金正明,仇惠英.急性早幼粒细胞白血病PML/RARα异型的临床意义[J].中国实验血液学杂志,2005,13(3):500-502. 被引量:8
  • 2Wang ZY,Chen Z.Acute promyelocytic leukemia:from highly fatal to highly curable[J].Blood,2008,111:2505-2515.
  • 3Haferlach T.Molecular genetic pathways as therapeutic targets in acute myeloid leukemia[J].Hematology Am Soc Hematol Educ Program,2008,2008:400-411.
  • 4WangZY, ChenZ. Acute promyelocytic leukemia: from highly fatal to highly curable [J]. Blood, 2008,111(5):2505-2515. doi: 10.1182/blood-2007-07-102798.
  • 5AdèsL, GuerciA, RaffouxE, et al. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience[J]. Blood, 2010, 115(9):1690-1696. doi: 10.1182/blood-2009-07-233387.
  • 6BurnettAK, HillsRK, GrimwadeD, et al. Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial [J]. Leukemia, 2013, 27(4):843-851. doi: 10.1038/leu.2012.360.
  • 7AvvisatiG, Lo-CocoF, PaoloniFP, et al. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance[J]. Blood, 2011, 117(18):4716-4725. doi: 10.1182/blood-2010-08-302950.
  • 8SanzMA, GrimwadeD, TallmanMS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European Leukemia Net[J]. Blood, 2009, 113(9):1875-1891. doi: 10.1182/blood-2008-04-150250.
  • 9SanzMA, MartínG, GonzálezM, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group [J]. Blood, 2004, 103(4):1237-1243. doi: 10.1182/blood-2003-07-2462.
  • 10SanzMA, LoCF, MartínG, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups[J]. Blood, 2000, 96(4):1247-1253.

共引文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部